Healthcare company DexCom, Inc. (NASDAQ: DXCM) announced preliminary results for the fourth quarter of 2023, reporting an estimated double-digit increase in revenues.
- Fourth-quarter revenue, unaudited, is expected to be at least $1.03 billion, which represents an increase of 26% over the same period of 2022
- US revenue is expected to be around $765 million in the December quarter, which is up 26% over the fourth quarter of the prior year
- At $265 million, international revenue is estimated to be higher by 27% from the prior-year quarter
- Stelo, the company’s new glucose sensor for people with type-2 diabetes who do not use insulin, has been submitted to the FDA for review
- For FY24, the company expects revenues of $4.15-4.35 billion, representing expected organic growth of 16-21% Year-over-year
- Full-year adjusted gross profit margin is expected to be approximately 63 – 64%
- The management is looking for an adjusted operating margin of around 20% for fiscal 2024
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
MDT Earnings: Highlights of Medtronic’s Q2 2025 financial results
Medical device maker Medtronic plc (NYSE: MDT) reported a modest increase in revenues and adjusted profit for the second quarter of 2025. Second-quarter earnings, excluding special items, rose 1% year-over-year
WMT Earnings: Walmart Q3 sales and profit rise and beat estimates
Retail giant Walmart Inc. (NYSE: WMT) on Tuesday announced financial results for the third quarter of 2025, reporting an increase in sales and net profit. The numbers also topped expectations.
LOW Earnings: Key quarterly highlights from Lowe’s Q3 2024 financial results
Lowe's Companies, Inc. (NYSE: LOW) reported its third quarter 2024 earnings results today. Total sales were $20.2 billion, compared to $20.5 billion in the prior-year quarter. Comparable sales decreased 1.1%.
